FogPharma Stock

fogpharma.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $506.63MM

FogPharma is a clinical-stage biotechnology research company striving to develop HeliconTM peptides, an innovative approach aimed at overcoming current medication limitations and creating drug solutions for all human disease drivers. The Helicons are intended to act similarly to antibodies and be allocated across tissue as they interact with small molecules within the cells, whereas most modern tailored medications have difficulty reaching these target areas. FogPharma was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for FogPharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access FogPharma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like FogPharma.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

FogPharma investors also invested in these private companies

6 Dimensions Capital
Milky Way Investments Group
PagsGroup
Blue Pool Capital
Leerink Partners
Boyu Capital

Team

Management Team

Mathai Mammen MD, Ph.D.
Chief Executive Officer & President
Rohin Mhatre Ph.D
Chief Technical Operations Officer
Gregory Miller MPH, MBA
Chief Business Officer
Keith Orford MD
Chief Medical Officer & Executive Vice President of Clinical and Translational Science
Kristen Stants MILR
Chief People Officer

Board Members

Jeffrey Leerink
Leerink Partners
Krishna Yeshwant MD
GV
Alexis Borisy
Nextech Invest

FogPharma stock FAQs

plusminus

Can you buy FogPharma stock?

As FogPharma is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like FogPharma, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.
plusminus

How to buy FogPharma stock?

To invest in a private company like FogPharma through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell FogPharma stock?

Yes, you may be able to sell your FogPharma stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell FogPharma stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your FogPharma stock on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.
plusminus

Is FogPharma a public company?

No, FogPharma is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is FogPharma’s stock price?

FogPharma is a privately held company and therefore does not have a public stock price. However, you may access FogPharma’s private market stock price with Forge Data.
plusminus

What is FogPharma’s stock ticker symbol?

FogPharma does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
FogPharma elevated its financing with a series E funding round to continue its cancer pharmaceutical research expansion.
FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
FogPharma has netted a $178 Million Series D financing to develop Helicon polypeptide therapeutics against hard targets.
/PRNewswire/ -- FogPharma today announced the appointment of Fang Wang, Ph.D., as Vice President of Biology and Nancy Wilker, Ph.D., J.D., as Vice President...
Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.